Development of Potent/Selective Lipoxygenase Therapeutics against Stroke Injury

Investigator: Matthew Jacobson, PhD
Sponsor: UC Santa Cruz

Location(s): United States


The principle aim of this research is to develop selective and potent human 12/15-LOX inhibitors, which will probe the role of inflammation in stroke, leading to drug candidates for this devastating human disease. Recent failures in testing of neuroprotective agents have highlighted the need for new approaches to acute stroke treatment. Among the novel targets, 12/15-lipoxygenase (12/15-LOX or 15-LOX-1) stands out for numerous reasons.